Immunome (IMNM) Financials

$7.40 +0.05 (+0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$7.25 -0.15 (-2.03%)

As of 06:20 PM Eastern

Annual Income Statements for Immunome

This table shows Immunome's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-38	-107	-293
Consolidated Net Income / (Loss)	-37	-107	-293
Net Income / (Loss) Continuing Operations	-37	-107	-293
Total Pre-Tax Income	-37	-107	-293
Total Operating Income	-37	-110	-306
Total Gross Profit	0.00	14	9.04
Total Revenue	0.00	14	9.04
Operating Revenue	0.00	14	9.04
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	37	124	315
Selling, General & Admin Expense	14	20	33
Research & Development Expense	23	104	282
Total Other Income / (Expense), net	0.01	2.72	13
Interest Expense	-0.01	-2.72	-13
Basic Earnings per Share	($3.09)	($5.38)	($5.00)
Weighted Average Basic Shares Outstanding	12.13M	19.84M	58.64M
Diluted Earnings per Share	($3.09)	($5.38)	($5.00)
Weighted Average Diluted Shares Outstanding	12.13M	19.84M	58.64M
Weighted Average Basic & Diluted Shares Outstanding	12.22M	59.69M	86.95M

This table shows Immunome's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-9.16	-28	-4.27	-5.56	-4.35	-93	-129	-36	-47	-80
Consolidated Net Income / (Loss)	-8.53	-7.79	-4.27	-5.56	-4.35	-93	-129	-36	-47	-80
Net Income / (Loss) Continuing Operations	-8.53	-7.79	-4.27	-5.56	-4.35	-93	-129	-36	-47	-80
Total Pre-Tax Income	-8.53	-7.79	-4.27	-5.56	-4.35	-93	-129	-36	-47	-80
Total Operating Income	-8.53	-7.79	-4.47	-5.77	-4.63	-95	-132	-40	-51	-83
Total Gross Profit	0.00	-	2.36	4.26	3.57	3.83	1.03	2.36	2.91	2.74
Total Revenue	0.00	-	2.36	4.26	3.57	3.83	1.03	2.36	2.91	2.74
Operating Revenue	0.00	-	2.36	4.26	3.57	3.83	1.03	2.36	2.91	2.74
Total Operating Expenses	8.53	7.79	6.84	10	8.20	98	133	42	53	86
Selling, General & Admin Expense	3.31	3.54	2.92	4.32	4.38	8.04	6.01	6.98	9.53	10
Research & Development Expense	5.23	4.25	3.91	5.72	3.82	90	127	35	44	75
Total Other Income / (Expense), net	0.00	0.00	0.20	0.22	0.29	2.02	2.81	3.89	3.42	2.72
Interest Expense	-0.00	-0.00	-0.20	-0.22	-0.29	-2.02	-2.81	-3.89	-3.42	-2.72
Basic Earnings per Share	($0.75)	($0.64)	($0.35)	($0.46)	($0.36)	($4.21)	($2.51)	($0.60)	($0.78)	($1.11)
Weighted Average Basic Shares Outstanding	12.13M	12.13M	12.18M	12.20M	12.20M	19.84M	51.54M	59.94M	60.21M	58.64M
Diluted Earnings per Share	($0.75)	($0.64)	($0.35)	($0.46)	($0.36)	($4.21)	($2.51)	($0.60)	($0.78)	($1.11)
Weighted Average Diluted Shares Outstanding	12.13M	12.13M	12.18M	12.20M	12.20M	19.84M	51.54M	59.94M	60.21M	58.64M
Weighted Average Basic & Diluted Shares Outstanding	12.13M	12.22M	12.22M	12.20M	42.73M	59.69M	59.97M	60.05M	62.42M	86.95M

This table details how cash moves in and out of Immunome's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-29	78	45
Net Cash From Operating Activities	-29	-7.57	-111
Net Cash From Continuing Operating Activities	-29	-7.57	-111
Net Income / (Loss) Continuing Operations	-37	-107	-293
Consolidated Net Income / (Loss)	-37	-107	-293
Depreciation Expense	0.42	0.46	1.57
Amortization Expense	0.21	-0.24	-2.36
Non-Cash Adjustments To Reconcile Net Income	5.33	87	168
Changes in Operating Assets and Liabilities, net	2.24	12	15
Net Cash From Investing Activities	-0.25	-30	-85
Net Cash From Continuing Investing Activities	-0.25	-30	-85
Purchase of Property, Plant & Equipment	-0.25	-0.83	-7.17
Acquisitions	-	0.00	-46
Purchase of Investments	0.00	-39	-187
Divestitures	0.00	9.28	0.00
Sale and/or Maturity of Investments	-	0.00	155
Net Cash From Financing Activities	0.03	116	241
Net Cash From Continuing Financing Activities	0.03	116	241
Issuance of Debt	-	0.00	230
Issuance of Common Equity	0.00	125	20
Other Financing Activities, net	0.03	-8.63	-9.47

This table details how cash moves in and out of Immunome's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-7.57	-6.76	24	-6.01	52	8.04	171	-104	-9.76	-12
Net Cash From Operating Activities	-7.57	-6.68	24	-5.67	-8.61	-17	-11	-23	-34	-42
Net Cash From Continuing Operating Activities	-7.57	-6.68	24	-5.67	-8.61	-17	-11	-23	-34	-42
Net Income / (Loss) Continuing Operations	-8.53	-7.79	-4.27	-5.56	-4.35	-93	-129	-36	-47	-80
Consolidated Net Income / (Loss)	-8.53	-7.79	-4.27	-5.56	-4.35	-93	-129	-36	-47	-80
Depreciation Expense	0.10	0.10	0.09	0.10	0.11	0.15	0.16	0.55	0.41	0.45
Amortization Expense	0.01	0.17	0.05	0.06	0.39	-0.74	-0.43	-0.23	-1.31	-0.39
Non-Cash Adjustments To Reconcile Net Income	1.34	1.36	1.16	1.03	1.09	84	114	9.50	12	33
Changes in Operating Assets and Liabilities, net	-0.49	-0.51	27	-1.30	-5.85	-8.14	4.51	2.91	2.31	5.21
Net Cash From Investing Activities	-	-0.07	-0.11	-0.34	-0.04	-30	-37	-82	24	9.76
Net Cash From Continuing Investing Activities	-	-0.07	-0.11	-0.34	-0.04	-30	-37	-82	24	9.76
Purchase of Property, Plant & Equipment	-	-0.07	-0.11	-0.34	-0.04	-0.35	-2.16	-2.34	-1.54	-1.13
Acquisitions	-	-	0.00	-	-	-	-35	-6.66	-4.36	-0.25
Purchase of Investments	-	-	-	-	-	-39	-	-	-	-74
Sale and/or Maturity of Investments	-	-	-	-	-	-	-	-	30	85
Net Cash From Financing Activities	-	-	0.03	-	61	55	219	0.69	0.31	20
Net Cash From Continuing Financing Activities	-	-	0.03	-	61	55	219	0.69	0.31	20
Issuance of Common Equity	-	-	0.03	-	61	64	0.00	-	-	20
Other Financing Activities, net	-	-	0.00	-	-0.13	-8.50	-11	0.69	0.31	0.09

This table presents Immunome's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	24	149	240
Total Current Assets	23	145	221
Cash & Equivalents	20	99	143
Short-Term Investments	0.00	39	74
Prepaid Expenses	2.33	6.56	4.04
Plant, Property, & Equipment, net	0.68	2.07	10
Total Noncurrent Assets	0.72	1.76	8.79
Other Noncurrent Operating Assets	0.72	1.76	8.79
Total Liabilities & Shareholders' Equity	24	149	240
Total Liabilities	7.39	29	59
Total Current Liabilities	7.33	22	54
Accounts Payable	2.40	3.31	14
Accrued Expenses	4.93	8.03	33
Current Deferred Revenue	0.00	10	6.94
Total Noncurrent Liabilities	0.06	6.83	4.77
Noncurrent Deferred Revenue	0.00	5.49	0.00
Other Noncurrent Operating Liabilities	0.06	1.34	4.77
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	17	120	181
Total Preferred & Common Equity	17	120	181
Preferred Stock	0.00	0.00	0.00
Total Common Equity	17	120	181
Common Stock	133	343	697
Retained Earnings	-116	-223	-516
Accumulated Other Comprehensive Income / (Loss)	0.00	0.02	0.06

This table presents Immunome's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	31	48	41	93	320	296	257
Total Current Assets	29	47	40	91	313	284	244
Cash & Equivalents	27	44	38	91	270	165	156
Short-Term Investments	-	-	-	-	40	113	85
Prepaid Expenses	2.16	2.11	1.11	0.77	3.62	5.93	3.91
Plant, Property, & Equipment, net	0.70	0.92	1.20	1.17	4.30	6.10	7.17
Total Noncurrent Assets	0.60	0.66	0.71	0.58	2.13	5.84	5.69
Other Noncurrent Operating Assets	0.60	0.66	0.71	0.58	2.13	5.84	5.69
Total Liabilities & Shareholders' Equity	31	48	41	93	320	296	257
Total Liabilities	7.46	34	32	87	34	42	42
Total Current Liabilities	7.37	25	26	23	31	40	40
Accounts Payable	3.14	3.31	3.70	2.79	7.18	7.05	3.52
Accrued Expenses	4.23	3.31	5.03	3.37	11	20	26
Current Deferred Revenue	-	18	18	17	13	13	9.68
Total Noncurrent Liabilities	0.09	9.42	5.71	64	3.41	2.48	2.46
Noncurrent Deferred Revenue	-	9.42	5.71	2.85	2.21	0.00	0.00
Other Noncurrent Operating Liabilities	0.09	0.00	0.00	61	1.21	2.48	2.46
Total Equity & Noncontrolling Interests	23	14	9.34	6.08	286	254	215
Total Preferred & Common Equity	23	14	9.34	6.08	286	254	215
Preferred Stock	0.00	0.00	-	0.00	0.00	0.00	0.00
Total Common Equity	23	14	9.34	6.08	286	254	215
Common Stock	131	134	135	136	638	642	650
Retained Earnings	-108	-120	-126	-130	-352	-388	-436
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	0.00	0.00	0.07

This table displays calculated financial ratios and metrics derived from Immunome's official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	-35.50%
EBITDA Growth	-51.47%	-201.39%	-180.47%
EBIT Growth	-49.39%	-196.82%	-179.19%
NOPAT Growth	-46.41%	-196.82%	-179.19%
Net Income Growth	-49.31%	-189.48%	-174.29%
EPS Growth	-44.39%	-74.11%	7.06%
Operating Cash Flow Growth	-57.41%	73.62%	-1,363.98%
Free Cash Flow Firm Growth	-59.81%	-167.54%	-216.01%
Invested Capital Growth	-251.53%	-397.55%	-97.91%
Revenue Q/Q Growth	0.00%	37.54%	-10.74%
EBITDA Q/Q Growth	0.55%	-406.06%	3.87%
EBIT Q/Q Growth	0.15%	-383.28%	3.68%
NOPAT Q/Q Growth	0.15%	-383.28%	3.68%
Net Income Q/Q Growth	0.18%	-386.41%	4.06%
EPS Q/Q Growth	0.64%	-197.24%	38.27%
Operating Cash Flow Q/Q Growth	0.42%	-335.91%	-28.54%
Free Cash Flow Firm Q/Q Growth	0.52%	-195.94%	30.33%
Invested Capital Q/Q Growth	8.11%	78.41%	-43.27%
Profitability Metrics	-	-	-
Gross Margin	0.00%	100.00%	100.00%
EBITDA Margin	0.00%	-779.81%	-3,391.18%
Operating Margin	0.00%	-781.35%	-3,382.37%
EBIT Margin	0.00%	-781.35%	-3,382.37%
Profit (Net Income) Margin	0.00%	-761.92%	-3,240.38%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	99.99%	97.51%	95.80%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-113.81%	-156.45%	-194.63%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-126.93%	-157.31%
Return on Assets (ROA)	0.00%	-123.77%	-150.71%
Return on Common Equity (ROCE)	-113.81%	-156.45%	-194.63%
Return on Equity Simple (ROE_SIMPLE)	-221.56%	-89.09%	-161.71%
Net Operating Profit after Tax (NOPAT)	-26	-77	-214
NOPAT Margin	0.00%	-546.95%	-2,367.66%
Net Nonoperating Expense Percent (NNEP)	-31.82%	-38.03%	-44.40%
Return On Investment Capital (ROIC_SIMPLE)	-	-63.96%	-118.16%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	140.23%	364.51%
R&D to Revenue	0.00%	741.13%	3,117.86%
Operating Expenses to Revenue	0.00%	881.35%	3,482.37%
Earnings before Interest and Taxes (EBIT)	-37	-110	-306
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-36	-109	-307
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.61	3.81	3.66
Price to Tangible Book Value (P/TBV)	1.61	3.81	3.66
Price to Revenue (P/Rev)	0.00	32.62	73.32
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	22.76	49.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.07	-1.16	-1.18
Leverage Ratio	1.26	1.26	1.29
Compound Leverage Factor	1.26	1.23	1.24
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-8.88	6.13	0.40
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.09	6.63	4.08
Quick Ratio	2.77	6.33	4.00
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-23	-62	-196
Operating Cash Flow to CapEx	-11,568.55%	-910.71%	-1,544.60%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.16	0.05
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	10.18	1.48
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-3.67	-18	-36
Invested Capital Turnover	0.00	-1.28	-0.33
Increase / (Decrease) in Invested Capital	-2.63	-15	-18
Enterprise Value (EV)	6.48	319	446
Market Capitalization	27	457	663
Book Value per Share	$1.37	$2.81	$2.90
Tangible Book Value per Share	$1.37	$2.81	$2.90
Total Capital	17	120	181
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-20	-138	-217
Capital Expenditures (CapEx)	0.25	0.83	7.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.01	-15	-50
Debt-free Net Working Capital (DFNWC)	15	123	167
Net Working Capital (NWC)	15	123	167
Net Nonoperating Expense (NNE)	11	30	79
Net Nonoperating Obligations (NNO)	-20	-138	-217
Total Depreciation and Amortization (D&A)	0.63	0.22	-0.80
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-108.92%	-556.03%
Debt-free Net Working Capital to Revenue	0.00%	876.54%	1,847.49%
Net Working Capital to Revenue	0.00%	876.54%	1,847.49%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($3.09)	($5.38)	($5.00)
Adjusted Weighted Average Basic Shares Outstanding	12.13M	19.84M	58.64M
Adjusted Diluted Earnings per Share	($3.09)	($5.38)	($5.00)
Adjusted Weighted Average Diluted Shares Outstanding	12.13M	19.84M	58.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.22M	59.69M	86.95M
Normalized Net Operating Profit after Tax (NOPAT)	-26	-77	-214
Normalized NOPAT Margin	0.00%	-546.95%	-2,367.66%
Pre Tax Income Margin	0.00%	-761.92%	-3,240.38%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Immunome's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-56.47%	-44.55%	-18.37%	-28.44%
EBITDA Growth	-13.31%	2.58%	62.47%	36.22%	50.89%	-1,165.31%	-2,966.71%	-606.70%	-1,143.63%	12.95%
EBIT Growth	-10.59%	0.73%	61.64%	35.32%	45.71%	-1,115.53%	-2,859.05%	-593.04%	-990.48%	12.34%
NOPAT Growth	-10.50%	0.73%	61.64%	35.32%	45.71%	-1,115.53%	-2,859.05%	-593.04%	-990.48%	12.34%
Net Income Growth	-10.53%	0.84%	63.36%	37.73%	49.08%	-1,089.75%	-2,932.60%	-550.03%	-984.00%	13.37%
EPS Growth	-15.38%	3.03%	63.54%	37.84%	52.00%	-557.81%	-617.14%	-30.43%	-116.67%	73.63%
Operating Cash Flow Growth	-82.65%	1.79%	479.12%	29.68%	-13.78%	-161.24%	-146.21%	-312.79%	-296.65%	-140.91%
Free Cash Flow Firm Growth	68.58%	-19.30%	2,244.51%	1,999.00%	2,354.59%	-1,728.99%	-541.59%	-257.61%	-222.47%	22.19%
Invested Capital Growth	-175.45%	-251.53%	-510.63%	-565.10%	-2,017.30%	-397.55%	21.03%	15.69%	70.17%	-97.91%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	80.33%	-16.37%	7.32%	-73.11%	129.74%	23.10%	-5.91%
EBITDA Q/Q Growth	4.37%	10.61%	42.57%	-29.91%	26.37%	-2,203.26%	-39.69%	70.06%	-29.57%	-61.23%
EBIT Q/Q Growth	4.39%	8.75%	42.58%	-29.12%	19.75%	-1,943.02%	-39.77%	69.76%	-26.28%	-64.23%
NOPAT Q/Q Growth	4.39%	8.75%	42.58%	-29.12%	19.75%	-1,943.02%	-39.77%	69.76%	-26.28%	-64.23%
Net Income Q/Q Growth	4.38%	8.75%	45.16%	-30.14%	21.81%	-2,031.97%	-39.79%	72.10%	-30.39%	-70.38%
EPS Q/Q Growth	-1.35%	14.67%	45.31%	-31.43%	21.74%	-1,069.44%	40.38%	76.10%	-30.00%	-42.31%
Operating Cash Flow Q/Q Growth	6.07%	11.73%	461.71%	-123.45%	-51.98%	-102.68%	36.02%	-109.46%	-46.03%	-23.10%
Free Cash Flow Firm Q/Q Growth	-215.18%	17.64%	893.91%	-7.86%	274.20%	-166.82%	-91.68%	67.11%	-190.78%	57.55%
Invested Capital Q/Q Growth	8.65%	8.11%	-732.75%	4.86%	-190.82%	78.41%	-32.17%	-1.58%	-2.89%	-43.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	-182.87%	-131.74%	-115.99%	-2,489.28%	-12,883.77%	-1,678.85%	-1,767.15%	-3,028.16%
Operating Margin	0.00%	0.00%	-189.13%	-135.42%	-129.96%	-2,473.94%	-12,857.05%	-1,692.43%	-1,736.15%	-3,030.31%
EBIT Margin	0.00%	0.00%	-189.13%	-135.42%	-129.96%	-2,473.94%	-12,857.05%	-1,692.43%	-1,736.15%	-3,030.31%
Profit (Net Income) Margin	0.00%	0.00%	-180.63%	-130.35%	-121.88%	-2,421.17%	-12,584.26%	-1,528.00%	-1,618.56%	-2,930.94%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	99.99%	99.99%	95.50%	96.26%	93.78%	97.87%	97.88%	90.28%	93.23%	96.72%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-94.92%	-113.81%	-114.09%	-132.00%	-150.60%	-156.45%	-154.98%	-199.56%	-276.36%	-194.63%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	-9.33%	-22.31%	-21.41%	-401.88%	-886.55%	-108.11%	-100.47%	-140.94%
Return on Assets (ROA)	0.00%	0.00%	-8.91%	-21.47%	-20.08%	-393.31%	-867.74%	-97.60%	-93.67%	-136.32%
Return on Common Equity (ROCE)	-94.92%	-113.81%	-114.09%	-132.00%	-150.60%	-156.45%	-154.98%	-199.56%	-276.36%	-194.63%
Return on Equity Simple (ROE_SIMPLE)	-160.12%	0.00%	-212.91%	-280.00%	-361.39%	0.00%	-81.25%	-103.45%	-142.08%	0.00%
Net Operating Profit after Tax (NOPAT)	-5.97	-5.45	-3.13	-4.04	-3.24	-66	-93	-28	-35	-58
NOPAT Margin	0.00%	0.00%	-132.39%	-94.79%	-90.97%	-1,731.76%	-8,999.93%	-1,184.70%	-1,215.31%	-2,121.22%
Net Nonoperating Expense Percent (NNEP)	-6.14%	-6.71%	-2.61%	-4.15%	-1.87%	-33.29%	-20.83%	-5.12%	-7.10%	-12.47%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-55.27%	-	-	-	-32.06%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	123.60%	101.34%	122.72%	210.14%	583.58%	295.18%	327.35%	381.52%
R&D to Revenue	0.00%	0.00%	165.52%	134.08%	107.24%	2,363.80%	12,373.47%	1,497.25%	1,508.80%	2,748.79%
Operating Expenses to Revenue	0.00%	0.00%	289.13%	235.42%	229.96%	2,573.94%	12,957.05%	1,792.43%	1,836.15%	3,130.31%
Earnings before Interest and Taxes (EBIT)	-8.53	-7.79	-4.47	-5.77	-4.63	-95	-132	-40	-51	-83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-8.42	-7.53	-4.32	-5.62	-4.14	-95	-133	-40	-51	-83
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.33	1.61	4.40	10.35	16.77	3.81	5.16	2.86	4.09	3.66
Price to Tangible Book Value (P/TBV)	2.33	1.61	4.40	10.35	16.77	3.81	5.16	2.86	4.09	3.66
Price to Revenue (P/Rev)	0.00	0.00	25.78	14.58	10.00	32.62	116.16	67.29	86.68	73.32
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	6.99	8.78	1.10	22.76	91.74	41.48	62.97	49.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	8.89	13.69	3.51	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	3.48	9.53	0.17	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.07	-1.07	-1.69	-1.84	-4.04	-1.16	-1.18	-1.20	-1.50	-1.18
Leverage Ratio	1.20	1.26	1.85	2.03	4.24	1.26	1.23	1.28	1.58	1.29
Compound Leverage Factor	1.20	1.26	1.77	1.95	3.98	1.24	1.20	1.16	1.48	1.25
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.69	-4.88	-2.15	-2.36	-0.43	6.46	24.05	9.02	10.52	3.46
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.97	3.09	1.87	1.50	3.96	6.63	10.18	7.12	6.17	4.08
Quick Ratio	3.67	2.77	1.79	1.46	3.92	6.33	10.07	6.98	6.07	4.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3.43	-2.82	22	21	77	-52	-99	-33	-95	-40
Operating Cash Flow to CapEx	0.00%	-9,281.94%	22,804.72%	-1,667.06%	-23,927.78%	-5,002.58%	-516.17%	-998.17%	-2,220.08%	-3,735.35%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.05	0.16	0.16	0.16	0.07	0.06	0.06	0.05
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	2.83	6.59	10.87	10.18	4.86	2.95	2.43	1.48
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-3.99	-3.67	-31	-29	-85	-18	-24	-25	-25	-36
Invested Capital Turnover	0.00	0.00	-0.13	-0.40	-0.23	-1.28	-0.46	-0.40	-0.18	-0.33
Increase / (Decrease) in Invested Capital	-2.54	-2.63	-26	-25	-81	-15	6.43	4.56	59	-18
Enterprise Value (EV)	27	6.48	17	58	11	319	1,164	447	638	446
Market Capitalization	54	27	61	97	102	457	1,473	726	878	663
Book Value per Share	$1.90	$1.37	$1.13	$0.76	$0.50	$2.81	$4.78	$4.23	$3.58	$2.90
Tangible Book Value per Share	$1.90	$1.37	$1.13	$0.76	$0.50	$2.81	$4.78	$4.23	$3.58	$2.90
Total Capital	23	17	14	9.34	6.08	120	286	254	215	181
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-27	-20	-44	-38	-91	-138	-310	-278	-240	-217
Capital Expenditures (CapEx)	0.00	0.07	0.11	0.34	0.04	0.35	2.16	2.34	1.54	1.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.21	-5.01	-23	-25	-22	-15	-27	-34	-36	-50
Debt-free Net Working Capital (DFNWC)	22	15	22	13	68	123	283	244	205	167
Net Working Capital (NWC)	22	15	22	13	68	123	283	244	205	167
Net Nonoperating Expense (NNE)	2.56	2.34	1.14	1.52	1.10	26	37	8.12	12	22
Net Nonoperating Obligations (NNO)	-27	-20	-44	-38	-91	-138	-310	-278	-240	-217
Total Depreciation and Amortization (D&A)	0.11	0.26	0.15	0.16	0.50	-0.59	-0.28	0.32	-0.90	0.06
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-961.04%	-381.50%	-219.17%	-108.92%	-214.05%	-314.99%	-351.64%	-556.03%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	918.15%	198.19%	670.16%	876.54%	2,227.85%	2,266.17%	2,019.07%	1,847.49%
Net Working Capital to Revenue	0.00%	0.00%	918.15%	198.19%	670.16%	876.54%	2,227.85%	2,266.17%	2,019.07%	1,847.49%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.75)	($0.64)	($0.35)	($0.46)	($0.36)	($4.21)	($2.51)	($0.60)	($0.78)	($1.11)
Adjusted Weighted Average Basic Shares Outstanding	12.13M	12.13M	12.18M	12.20M	12.20M	19.84M	51.54M	59.94M	60.21M	58.64M
Adjusted Diluted Earnings per Share	($0.75)	($0.64)	($0.35)	($0.46)	($0.36)	($4.21)	($2.51)	($0.60)	($0.78)	($1.11)
Adjusted Weighted Average Diluted Shares Outstanding	12.13M	12.13M	12.18M	12.20M	12.20M	19.84M	51.54M	59.94M	60.21M	58.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.13M	12.22M	12.22M	12.20M	42.73M	59.69M	59.97M	60.05M	62.42M	86.95M
Normalized Net Operating Profit after Tax (NOPAT)	-5.97	-5.45	-3.13	-4.04	-3.24	-66	-93	-28	-35	-58
Normalized NOPAT Margin	0.00%	0.00%	-132.39%	-94.79%	-90.97%	-1,731.76%	-8,999.93%	-1,184.70%	-1,215.31%	-2,121.22%
Pre Tax Income Margin	0.00%	0.00%	-180.63%	-130.35%	-121.88%	-2,421.17%	-12,584.26%	-1,528.00%	-1,618.56%	-2,930.94%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Immunome's Financials

When does Immunome's financial year end?

According to the most recent income statement we have on file, Immunome's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Immunome's net income changed over the last 2 years?

Immunome's net income appears to be on an upward trend, with a most recent value of -$292.96 million in 2024, rising from -$36.90 million in 2022. The previous period was -$106.81 million in 2023.

What is Immunome's operating income?

Immunome's total operating income in 2024 was -$305.80 million, based on the following breakdown:

Total Gross Profit: $9.04 million
Total Operating Expenses: $314.84 million

How has Immunome revenue changed over the last 2 years?

Over the last 2 years, Immunome's total revenue changed from $0.00 in 2022 to $9.04 million in 2024, a change of 904,100,000.0%.

How much debt does Immunome have?

Immunome's total liabilities were at $59.08 million at the end of 2024, a 106.1% increase from 2023, and a 699.1% increase since 2022.

How much cash does Immunome have?

In the past 2 years, Immunome's cash and equivalents has ranged from $20.32 million in 2022 to $143.35 million in 2024, and is currently $143.35 million as of their latest financial filing in 2024.

How has Immunome's book value per share changed over the last 2 years?

Over the last 2 years, Immunome's book value per share changed from 1.37 in 2022 to 2.90 in 2024, a change of 111.4%.

Remove Ads

Related Companies

This page (NASDAQ:IMNM) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Financials

Frequently Asked Questions About Immunome's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunome (IMNM) Financials

Annual Income Statements for Immunome

Quarterly Income Statements for Immunome

Annual Cash Flow Statements for Immunome

Quarterly Cash Flow Statements for Immunome

Annual Balance Sheets for Immunome

Quarterly Balance Sheets for Immunome

Annual Metrics and Ratios for Immunome

Quarterly Metrics and Ratios for Immunome

Frequently Asked Questions About Immunome's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools